Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Acquired by Two Sigma Investments LP

Two Sigma Investments LP increased its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 92.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 275,594 shares of the company's stock after buying an additional 132,595 shares during the period. Two Sigma Investments LP owned about 0.48% of Harmony Biosciences worth $9,483,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Hillsdale Investment Management Inc. increased its position in Harmony Biosciences by 0.4% during the 4th quarter. Hillsdale Investment Management Inc. now owns 68,000 shares of the company's stock valued at $2,340,000 after purchasing an additional 300 shares during the period. O Shaughnessy Asset Management LLC increased its position in Harmony Biosciences by 2.1% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 20,450 shares of the company's stock valued at $704,000 after purchasing an additional 420 shares during the period. PNC Financial Services Group Inc. increased its position in Harmony Biosciences by 28.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company's stock valued at $80,000 after purchasing an additional 519 shares during the period. Aviva PLC increased its position in Harmony Biosciences by 3.9% during the 4th quarter. Aviva PLC now owns 18,072 shares of the company's stock valued at $622,000 after purchasing an additional 686 shares during the period. Finally, BOKF NA increased its position in Harmony Biosciences by 4.7% during the 4th quarter. BOKF NA now owns 15,400 shares of the company's stock valued at $521,000 after purchasing an additional 690 shares during the period. Hedge funds and other institutional investors own 86.23% of the company's stock.

Harmony Biosciences Price Performance

NASDAQ HRMY traded down $0.07 during trading hours on Wednesday, hitting $33.72. 691,712 shares of the company's stock traded hands, compared to its average volume of 602,261. Harmony Biosciences Holdings, Inc. has a 52-week low of $26.47 and a 52-week high of $41.61. The company has a market capitalization of $1.94 billion, a PE ratio of 15.98, a PEG ratio of 0.47 and a beta of 0.82. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. The firm's 50-day moving average is $31.52 and its 200-day moving average is $34.00.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.59 by $0.19. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The firm had revenue of $184.73 million during the quarter, compared to analyst estimates of $184.26 million. During the same quarter in the prior year, the firm posted $0.67 earnings per share. Harmony Biosciences's quarterly revenue was up 19.5% on a year-over-year basis. Equities analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Needham & Company LLC reissued a "buy" rating and set a $49.00 target price on shares of Harmony Biosciences in a research report on Tuesday, May 6th. UBS Group dropped their target price on shares of Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating on the stock in a research report on Monday, April 28th. Mizuho lifted their price objective on shares of Harmony Biosciences from $44.00 to $48.00 and gave the company an "outperform" rating in a research note on Thursday, May 15th. Cantor Fitzgerald upgraded shares of Harmony Biosciences to a "strong-buy" rating in a research note on Tuesday, May 13th. Finally, HC Wainwright reiterated a "buy" rating and issued a $70.00 target price on shares of Harmony Biosciences in a research note on Tuesday, April 8th. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $52.78.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.